Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

PURPOSE: ASTRIS study aimed the largest to evaluate the effectiveness and safety of second- or higher-line osimertinib in patients with advanced/metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non–small cell lung cancer (NSCLC) in the real-world setting. Here we report the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Zhang, He-Long, Jiang, Li-Yan, Shi, Yuan-Kai, Chen, Yuan, Yu, Jin-Ming, Zhou, Cai-Cun, He, Yong, Hu, Yan-Ping, Liang, Zong-An, Pan, Yue-Yin, Zhuo, Wen-Lei, Song, Yong, Wu, Gang, Chen, Gong-Yan, Lu, You, Zhang, Cui-Ying, Zhang, Yi-Ping, Cheng, Ying, Lu, Shun, Wang, Chang-Li, Zhou, Jian-Ying, Liu, Yun-Peng, He, Jian-Xing, Wang, Jie, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423102/
https://www.ncbi.nlm.nih.gov/pubmed/37316692
http://dx.doi.org/10.1007/s00432-023-04923-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423102/
https://www.ncbi.nlm.nih.gov/pubmed/37316692
http://dx.doi.org/10.1007/s00432-023-04923-8

Ejemplares similares